Scope of the Study
Hydrochlorothiazide is a thiazide diuretic i.e. water pill that prevents your body from consuming too much salt, which can lead to fluid retention. It reduces the amount of water in the body by increasing the flow of urine, which lowers blood pressure. Telmisartan mainly belongs to a particular group of medicines known as angiotensin II receptor antagonists. Telmisartan prevents the blood vessels from narrowing, which lowers blood pressure and improves blood flow. The combination of hydrochlorothiazide and telmisartan is generally used for the purpose of treating high blood pressure (hypertension). High blood pressure increases the workload on the heart and arteries. If it lasts long, the heart and arteries may not work properly. This can damage the blood vessels of the brain, heart, and kidneys and lead to stroke, heart failure, or kidney failure. Lower blood pressure can thereby reduce the risks of stroke as well as a heart attack. As a result, telmisartan relaxes the blood vessels. This lowers blood pressure thus increases the supply of blood as well as oxygen to the heart. In rare cases, hydrochlorothiazide and telmisartan can cause a condition that leads to the breakdown of skeletal muscle tissue and kidney failure.
The market study is being classified by Type (80 mg/12.5 mg tablets, 40 mg/12.5 mg tablets and 80 mg/25 mg tablets), by Application (Hypertension, Fluid Retention, Prevents Heart Attacks and Kidney Failure and Others) and major geographies with country level break-up.
Boehringer Ingelheim (Germany), Teva Pharmaceuticals (Israel), Lupin Pharmaceuticals (India), Mylan N.V. (United States), Alembic Pharmaceutical Ltd. (India), Torrent Pharmaceuticals (India), Macleods Pharmaceuticals Ltd. (India), Zydus Pharmaceuticals (India), Aurobindo Pharma Ltd. (India) and Zhejiang Huahai Pharmaceutical Co., Ltd. (China) are some of the key players profiled in the study.
The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that Asian Players will contribute to the maximum growth of Global Telmisartan and Hydrochlorothiazide Drug market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Telmisartan and Hydrochlorothiazide Drug market by Type, Application and Region.
On the basis of geography, the market of Telmisartan and Hydrochlorothiazide Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Number of Diagnostics Centres and Hospitals
- Growing Geriatric Population in Major Economies
- Increasing Heart Attack And Stroke Cases
- Increasing Awareness among People about Preventive Healthcare
- Increasing Healthcare Spending and Demand for Drug Therapy
- Growing Demand from Online Customers
- Stringent Government Rules and Regulations
- Side Effects Due to Telmisartan and Hydrochlorothiazide Drug
- Growth in the Healthcare Industry
- Increased Research and Development Activities
- A Rise in the Online Pharmacies
- Availability of Substitutes
FDA updated warnings for Heart Attack and Stroke Risk for Non-Steroidal Anti-Inflammatory Drugs.FDA clearing existing warnings in prescription drug labels and over the counter drug, the important labels to mention that non-steroidal anti-inflammatory drugs (NSAIDs) can increase the risk of a heart attack or stroke, may lead to death
Key Target AudienceManufacturers of Telmisartan and Hydrochlorothiazide Drug, Suppliers and Distributors of Telmisartan and Hydrochlorothiazide Drug, End-Users, Potential Investors, Market Research Firms, Regulatory Bodies and Others
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase